Page last updated: 2024-12-08

oxypeucadanin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

oxypeucadanin: furanocoumarin from W. Afr. medicinal plant Clausena anisata; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oxypeucedanin : A furanocoumarin that is 7H-furo[3,2-g][1]benzopyran-7-one substituted by a [(2S)-3,3-dimethyloxiran-2-yl]methoxy group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
ClausenagenusA plant genus of the family RUTACEAE. Members contain anethole and CARBAZOLES.[MeSH]RutaceaeA plant family in the order Sapindales that grows in warmer regions and has conspicuous flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID160544
CHEMBL ID1510267
CHEBI ID174722
SCHEMBL ID21986501
MeSH IDM0099002

Synonyms (43)

Synonym
(r)-oxypeucedanin
737-52-0
CHEBI:174722
4-[(3,3-dimethyloxiran-2-yl)methoxy]uro[3,2-g]chromen-7-one
smr000282822
MLS000856077
phosphorus, amorphous [un1338] [flammable solid]
phosphorus metal, 99.999%, red
phosphine [un2199] [poison gas]
oxypeucedanin
4-[(3,3-dimethyloxiran-2-yl)methoxy]furo[3,2-g]chromen-7-one
7h-furo[3,2-g][1]benzopyran-7-one, 4-((3,3-dimethyloxiranyl)methoxy)-, (s-)-
AKOS000276826
NCGC00245178-01
HMS2676A10
al8mv76msb ,
oxypeucadanin
(+-)-oxypeucedanin
unii-al8mv76msb
5-epoxyisopentenyloxypsoralene
(rs)-oxypeucedanin
7h-furo(3,2-g)(1)benzopyran-7-one, 4-((3,3-dimethyloxiranyl)methoxy)-
S9251
FT-0689396
AB00580068-06
4-((3,3-dimethyloxiran-2-yl)methoxy)-7h-furo[3,2-g]chromen-7-one
QTAGQHZOLRFCBU-UHFFFAOYSA-N
7h-furo[3,2-g][1]benzopyran-7-one, 4-[(3,3-dimethyl-2-oxiranyl)methoxy]-
CHEMBL1510267
SR-01000359949-1
sr-01000359949
AKOS030475077
HY-N0747
AS-35254
mfcd00419546
SCHEMBL21986501
CCG-267337
4-((3,3-dimethyl-2-oxiranyl)methoxy)-7h-furo(3,2-g)(1)benzopyran-7-one
7h-furo(3,2-g)(1)benzopyran-7-one, 4-((3,3-dimethyl-2-oxiranyl)methoxy)-
oxypeucedanin, (+/-)-
(+/-)-oxypeucedanin
CS-0009779
A909728

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"A high-performance liquid chromatographic method was developed and validated for the determination and pharmacokinetic study of oxypeucedanin hydrate and byak-angelicin after oral administration of Angelica dahurica extracts in mongrel dog plasma."( High-performance liquid chromatographic method for the determination and pharmacokinetic study of oxypeucedanin hydrate and byak-angelicin after oral administration of Angelica dahurica extracts in mongrel dog plasma.
Chen, Y; Fan, G; Lin, M; Wen, J; Wu, Y; Xie, Y, 2007
)
0.34
" The phamacokinetic parameters AUC and Cmax were significantly increased, indicating that coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel, and their effects were in the following order: oxypeucedanin> isoimperatorin> imperatorin."( [Effect investigation of coumarin constituents in Angelica dahurica on pharmacokinetics of docetaxel by LC-MS].
Dong, W; Guan, XJ; Guan, YM; Liang, XL; Liao, ZG; Zhao, GW; Zhu, WF, 2017
)
0.46
" This study was aimed at investigating the effects of Acori Tatarinowii Rhizoma volatile oil on the pharmacokinetic parameters of xanthotoxol, oxypeucedanin hydrate, and byakangelicin from Angelicae Dahuricae Radix in rat, and in vitro absorption behavior of the three compounds using rat everted gut sac, in situ single-pass intestinal perfusion, and Caco-2 cell monolayer models."( Effect of co-administration of Acori Tatarinowii Rhizoma volatile oil on pharmacokinetic fate of xanthotoxol, oxypeucedanin hydrate, and byakangelicin from Angelicae Dahuricae Radix in rat.
Bian, L; Jia, P; Liu, J; Shi, B; Wang, S; Zhang, Q; Zheng, X, 2020
)
0.56
" After validation, the established method was successfully applied to the stereoselective analysis of racemic oxypeucedanin in Angelica dahurica from different regions and the stereoselective pharmacokinetic investigation in rat."( Enantioseparation and determination of oxypeucedanin and its application to a stereoselective analysis in Angelica Dahuricae Radix and pharmacokinetic study of rats.
Ding, H; Li, Y; Shu, L; Tang, L; Wang, Y; Yang, J; Yao, Y, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
"To develop a rapid and efficient method of rapid resolution liquid chromatography (RRLC) combined with chemometrics for discriminating sulphur-fumigated Baizhi and controlling its quality."( Development of a rapid resolution liquid chromatographic method combined with chemometrics for quality control of Angelicae dahuricae radix.
Deng, R; Fan, G; Kuang, T; Lai, X; Meng, X; Zhang, J; Zhang, Y; Zhou, L,
)
0.13
"This study revealed that sulphur-fumigation is an inappropriate approach for processing crude drugs and should be prohibited, and that the proposed RRLC method combined with chemometrics demonstrated an efficient strategy for quality control of Baizhi."( Development of a rapid resolution liquid chromatographic method combined with chemometrics for quality control of Angelicae dahuricae radix.
Deng, R; Fan, G; Kuang, T; Lai, X; Meng, X; Zhang, J; Zhang, Y; Zhou, L,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" The phamacokinetic parameters AUC and Cmax were significantly increased, indicating that coumarin constituents in Angelica dahurica could promote the oral bioavailability of docetaxel, and their effects were in the following order: oxypeucedanin> isoimperatorin> imperatorin."( [Effect investigation of coumarin constituents in Angelica dahurica on pharmacokinetics of docetaxel by LC-MS].
Dong, W; Guan, XJ; Guan, YM; Liang, XL; Liao, ZG; Zhao, GW; Zhu, WF, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" Currently, there is no better intervention measure for renal injury caused by sunitinib therapy except reducing the dosage or stopping the medication."( Study on the mechanism and intervention strategy of sunitinib induced nephrotoxicity.
Hao, L; Wang, D; Wang, J; Xiao, J; Yuan, L, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
psoralensA furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency70.79460.010039.53711,122.0200AID1479
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency39.81073.548119.542744.6684AID743266
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
DNA polymerase betaHomo sapiens (human)Potency1.00000.022421.010289.1251AID485314
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency0.35480.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency0.35480.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency0.35480.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency7.58080.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (5.26)18.7374
1990's2 (5.26)18.2507
2000's14 (36.84)29.6817
2010's15 (39.47)24.3611
2020's5 (13.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other41 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]